8-K: Brainstorm Cell Therapeutics Amends Distribution Agreement, Leerink Partners Exits

Brainstorm Cell Therapeutics has amended its distribution agreement, removing Leerink Partners as an agent for its at-the-market equity offering program.

Summary

• Brainstorm Cell Therapeutics amended its distribution agreement on April 2, 2024.
• The amendment removes Leerink Partners as an agent for the company's at-the-market equity offering program.
• Raymond James & Associates remains as the sole agent under the agreement.
• The original distribution agreement, dated August 9, 2021, allowed for the sale of up to $100 million of common stock.
• The amendment terminates Leerink Partners' rights and obligations under the agreement, with certain exceptions related to expenses, termination, indemnity, and other legal matters.

Sentiment

Score: 6

Explanation: The document reflects a neutral operational change. While the removal of an agent could be seen as a slight negative, the company maintains its ability to raise capital through the ATM program.

Positives

• The company maintains an active at-the-market equity offering program with Raymond James as the sole agent.
• The amendment simplifies the distribution agreement by reducing the number of agents.

Negatives

• The departure of Leerink Partners as an agent may reduce the company's access to capital through the at-the-market offering program.

Risks

• The company now relies on a single agent, Raymond James, for its at-the-market equity offering program, which could pose a risk if Raymond James's capacity or willingness to act as agent changes.
• The termination of Leerink Partners' role could potentially impact the company's ability to raise capital efficiently.

Future Outlook

The company will continue to utilize the at-the-market equity offering program with Raymond James as the sole agent.

Management Comments

• Chaim Lebovits, President and Co-Chief Executive Officer, signed the amendment on behalf of Brainstorm Cell Therapeutics Inc.

Industry Context

This type of amendment to a distribution agreement is not uncommon in the biotech industry, as companies adjust their capital raising strategies and relationships with financial institutions.

Comparison to Industry Standards

• Many biotech companies utilize at-the-market (ATM) offerings to raise capital, often working with multiple agents to maximize reach and flexibility.
• The decision to reduce the number of agents is not unusual, and may be driven by strategic considerations or performance evaluations.
• Companies like Athersys and Mesoblast have also used ATM offerings, and their experiences could provide a benchmark for Brainstorm's approach.

Stakeholder Impact

• Shareholders may be impacted by the change in the distribution agreement, as it could affect the company's ability to raise capital.
• The company's relationship with its financial partners has been altered.

Next Steps

• Brainstorm Cell Therapeutics will continue to utilize the at-the-market equity offering program with Raymond James as the sole agent.
• The company may seek to add additional agents in the future.

Key Dates

Keywords

distribution agreement, at-the-market offering, equity offering, Leerink Partners, Raymond James, common stock, capital raise, agent